Efficacy of infliximab in treatment on inflammatory bowel disease and factors affecting the therapeutic effect.
- Author:
Youlian ZHOU
1
;
Ye CHEN
Author Information
1. Department of Gastroenterology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China. E-mail: lianyouzhou2006@163.com.
- Publication Type:Journal Article
- MeSH:
Anti-Inflammatory Agents, Non-Steroidal;
therapeutic use;
Antibodies, Monoclonal;
therapeutic use;
Gastrointestinal Agents;
therapeutic use;
Humans;
Inflammatory Bowel Diseases;
drug therapy;
Infliximab
- From:
Journal of Southern Medical University
2013;33(12):1833-1838
- CountryChina
- Language:Chinese
-
Abstract:
Infliximab has shown its superiority and safety in the treatment of inflammatory bowel disease (IBD) that failed to respond to traditional medical therapy, in refractory cases with obvious adverse reactions, and in "top-down therapy". For standardized and effective management of IBD, experts worldwide have consecutively issued the 2010 European ECCO guide, 2011 London consensus, and 2012 Chinese consensus. In this paper, based on the latest expert consensus worldwide, we reviewed the efficacy of infliximab treatment on IBD and the factors affecting its therapeutic effect.
